“…In the case of NOAC therapy, data about procedure-related bleeding complications around the time of cardiac device implantation were not enough, so it is recommended to interrupt NOAC therapy before the surgery, without heparin bridging [13] . In March 2018, Ricciardi et al published the first large randomized trial that compares the effects of continuing with interruption NOAC therapy, without heparin bridging before the CIED implantation [21] .…”